Alterations of The Stem-Like Properties in The Breast Cancer Cell Line MDA-MB-231 Induced by Single Pulsed Doxorubicin Treatment
By:
References
- Achuthan, S., Santhoshkumar, T. R., Prabhakar, J., Nair, S. A., Pillai, M. R. (2011). Drug-induced senescence generates chemoresistant stemlike cells with low reactive oxygen species.
J. Biol. Chem. ,286 (43), 37813–37829. - Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., Clarke, M. F. (2003). Prospective identification of tumorigenic breast cancer cells.
Proc. Natl. Acad. Sci. USA, 100 (7), 3983–3988. - Anonymous (2018).
R: A Language and Environment for Statistical Computing. R foundation for statistical computing, Vienna. Available from:https://www.R-project.org/ (accessed 20.01.2019). - Brooks, D. L. P., Schwab, L. P., Krutilina, R., Parke, D. N., Sethuraman, A., Hoogewijs, D., Schörg, A., Gotwald, L., Fan, M., Wenger, R. H., Seagroves, T. N. (2016).
ITGA6 is directly regulated by hypoxia- inducible factors and enriches for cancer stem cell activity and invasion in metastatic breast cancer models.Mol. Cancer ,15 , 26. - Cortós-Funes, H., Coronado, C. (2007). Role of anthracyclines in the era of targeted therapy.
Cardiovasc. Toxicol., 7 (2), 56–60. - Cox, J., Weinman, S. (2016). Mechanisms of doxorubicin resistance in hepatocellular carcinoma.
Hepat Oncol., 3 (1), 57–59. - Dasari, S., Tchounwou, P. B. (2014). Cisplatin in cancer therapy: Molecular mechanisms of action.
Eur. J. Pharmacol., 740 , 364–378. - Dean, M., Fojo, T., Bates, S. (2005). Tumour stem cells and drug resistance.
Nat. Rev. Cancer ,5 (4), 275–284. - Dean, M., Hamon, Y., Chimini, G. (2001). The human ATP-binding cassette transporter superfamily.
J. Lipid Res., 42 (7), 1007–1017. - Deng, X., Apple, S., Zhao, H., Song, J., Lee, M., Luo, W., Wu, X., Chung, D., Pietras, R. J., Chang, H. R. (2017) CD24 expression and differential resistance to chemotherapy in triple-negative breast cancer.
Oncotarget, 8 (24), 38294–38308. - El-Badawy, A., Ghoneim, M. A., Gabr, M. M., Salah, R. A., Mohamed, I. K., Amer, M., El-Badri, N. (2017). Cancer cell-soluble factors reprogram mesenchymal stromal cells to slow cycling, chemoresistant cells with a more stem-like state.
Stem Cell Res. Ther. ,8 (1), 254. - Erenpreisa, J., Ivanov, A., Wheatley, S. P., Kosmacek, E. A., Ianzini, F., Anisimov, A. P., Mackey, M., Davis, P. J., Illidge, T. M. (2008). Endopolyploidy in irradiated p53-deficient tumour cell lines: Persistence of cell division activity in giant cells expressing Aurora-B kinase.
Cell Biol. Int., 32 (9), 1044–1056. - Fei, F., Zhang, D., Yang, Z., Wang, S., Wang, X., Wu, Z., Wu, Q., Zhang, S. (2015). The number of polyploid giant cells and epithelial-mesenchymal transition-related proteins are associated with invasion and metastasis un human breast cancer.
J. Exp. Clin. Cancer Res., 34 , 158. - Freshney, R. I. (2011).
Culture of Animal Cells: A Manual of Basic Technique and Specialized Applications. Hoboken, NY.: Wiley-Blackwell. 728 pp. - Gewirtz, D. A. (1999). A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin.
Biochem. Pharmacol., 57 (7), 727–741. - Gottesman, M. M., Fojo, T., Bates, S. E. (2002). Multidrug resistance in cancer: Role of ATP-dependent transporters.
Nat. Rev. Cancer, 2 (1), 48–58. - Hafner, M., Niepel, M., Chung, M., Sorger, P. K. (2016). Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs.
Nat. Methods ,13 (6), 521–527. - Hafner, M., Niepel, M., Sorger, P. K. (2017). Alternative drug sensitivity metrics improve preclinical cancer pharmacogenomics.
Nat. Biotechnol., 35 (6), 52–54. - Holohan, C., Van Schaeybroeck, S., Longley, D. B., Johnston, P. G. (2013). Cancer drug resistance: An evolving paradigm.
Nat. Rev. Cancer ,13 (10), 714–726. - Hu, H., Wang, M., Guan, X., Yuan, Z., Liu, Z., Zou, C., Guiyu, W., Gao, X., Wang, X. (2018). Loss of ABCB4 attenuates the caspase-dependent apoptosis regulating resistance to 5-Fu in colorectal cancer.
Biosci Rep., 38 (1), BSR20171428. - Huang, Z. J., You, J., Luo, W. Y., Chen, B. S., Feng, Q. Z., Wu, B. L., Jiang, L., Luo, Q. (2015). Reduced tumorigenicity and drug resistance through the downregulation of octamer-binding protein 4 and Nanog transcriptional factor expression in human breast stem cells.
Mol. Med. Rep., 11 (3), 1647–1654. - Hwang-Verslues, W. W., Kuo, W. H., Chang, P. H., Pan, C. C., Wang, H. H., Tsai, S. T., Jeng, Y. M., Shew, J. Y., Kung, J. T., Chen, C. H., Lee, E. Y., Chang, K. J., Lee, W. H. (2009). Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers.
PLoS ONE ,4 (12), e8377. - Jia, D., Tan, Y., Liu, H., Ooi, S., Li, L., Wright, K., Bennett, S., Addison, C.L., Wang, L. (2016). Cardamonin reduces chemotherapy-enriched breast cancer stem-like cells in vitro and in vivo.
Oncotarget, 7 (1), 771–785. - Kibria, G., Hatakeyama, H., Akiyama, K., Hida, K., Harashima, H. (2014). Comparative study of the sensitivities of cancer cells to doxorubicin, and relationships between the effect of the drug-efflux pump P-gp.
Biol. Pharm. Bull. ,37 (12), 1926–1935. - Kim, W., Ryu, C. J. (2017). Cancer stem cell surface markers on normal stem cells.
BMB Rep., 50 (6), 285–298. - Leggett, S. E., Sim, J. Y., Rubins, J. E., Neronha, Z. J., Williams, K., Wong, I. Y. (2016). Morphological single cell profiling of the epithelial-mesenchymal transition.
Integr. Biol. (Camb)., 8 (11), 1133–1144. - Liang, Y., Zhong, Z., Huang, Y., Deng, W., Cao, J., Tsao, G., Liu, Q., Pei, D., Kang, T., Zeng, Y.X. (2010). Stem-like cancer cells are inducible by increasing genomic instability in cancer cells.
J. Biol. Chem. ,285 (7), 4931–4940. - Ling, G. Q., Chen, D. B., Wang, B. Q., Zhang, L. S. (2012). Expression of the pluripotency markers Oct3/4, Nanog and Sox2 in human breast cancer cell lines.
Oncol. Lett., 4 (6), 1264–1268. - Liu, P., Kumar, I. S., Brown, S., Kannappan, V., Tawari, P. E., Tang, J. Z., Jiang, W., Armesilla, A. L., Darling, J. L., Wang, W. (2013). Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells.
Brit. J. Cancer ,109 (7), 1876–1885. - Livak, K. J., Schmittgen, T. D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method.
Methods ,25 (4), 402–408. - McDermott, M., Eustace, A. J., Busschots, S., Breen, L., Crown, J., Clynes, M., O’Donovan N., Stordal, B. (2014).
In vitro development of chemotherapy and targeted therapy drug-resistant cancer cell lines: A practical guide with case studies.Front. Oncol. ,4 , 40. - Mckenna, M. T., Weis, J. A., Barnes, S. L., Tyson, D. R., Miga, I., Quaranta, V., Yankeelov, T. E. (2017). Modeling approach for the study of doxorubicin treatment in triple negative breast cancer.
Sc. Rep. ,7 (1), 5725. - Mirzayans, R., Andrais, B., Murray, D. (2018). Roles of polyploid/multinucleated giant cancer cells in metastasis and disease relapse following anticancer treatment.
Cancers, 10 , 118. - Moitra, K., Lou, H., Dean, M. (2011). Multidrug efflux pumps and cancer stem cells: Insights into multidrug resistance and therapeutic development.
Clin. Pharmacol. Ther. ,89 (4), 491–502. - Niu, N., Zhang, J., Zhang, N., Mercado-Uribe, I., Tao, F., Han, Z., Pathak, S., Multani, A. S., Kuang, J., Yao, J., Bast, R.C., Sood, A.K., Hung, M.-C., Liu, J. (2016). Linking genomic reorganization to tumor initiation via the giant cell cycle.
Oncogenesis, 5 , e281. - Nowell, P. C. (1976). The clonal evolution of tumor cell populations.
Science ,194 (4260), 23–28. - Rajaraman, R., Guernsey, D. L., Rajaraman, M. M., Rajaraman, S. R. (2006). Stem cells, senescence, neosis and self-renewal in cancer.
Cancer Cell Int. ,6 , 1–26. - Rivera, E., Gomez, H. (2010). Chemotherapy resistance in metastatic breast cancer: The evolving role of ixabepilone.
Breast Cancer Res., 12 (Suppl 2), S2. - Saxena, M., Stephens, M. A., Pathak, H., Rangarajan, A. (2011). Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters.
Cell Death Dis. ,2 , e179. - Sheridan, C., Kishimoto, H., Fuchs, R. K., Mehrotra, S., Bhat-Nakshatri, P., Turner, C. H., Goulet, R. Jr., Badve, S., Nakshatri, H. (2006). CD44+/CD24-Breast cancer cells exhibit enhanced invase properties: An early step necessary for metastasis.
Breast Cancer Res. ,8 (5), R59. - Skehan, P., Storeng, R., Scudiero, D., Monks, A., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., Boyd, M. R. (1990). New colorimetric cytotoxicity assay for anticancer-drug screening.
J. Natl. Cancer Inst., 82 (13), 1107–1112. - Smith, L. Watson, M. B., O’Kane, S. L., Drew, P. J., Lind, M. J., Cawkwell, L. (2006). The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays.
Mol. Cancer Ther., 5 (8), 2115–2120. - Sun, L., Cabarcas, S. M., Farrar, W. L. (2012). Radioresistance and cancer stem cells: Survival of the fittest.
J. Carcinogene Mutagenes ,s1 (01), 1–12. - Sundaram, M., Guernsey, D. L., Rajaraman, M. M., Rajaraman, R. (2004). Neosis: A novel type of cell division in cancer.
Cancer Biol. Ther., 3 , 2017–2218. - Tegze, B., Szállási, Z., Haltrich, I., Pénzváltó, Z., Tóth, Z., Likó, I., Gyorffy, B. (2012). Parallel evolution under chemotherapy pressure in 29 breast cancer cell lines results in dissimilar mechanisms of resistance.
PLoS ONE ,7 (2), 1–9. - Vassilopoulos, A., Chisholm, C., Lahusen, T., Zheng, H., Deng, C. (2013). A critical role of CD29 and CD49f in mediating metastasis for cancer-initiating cells isolated from a Brca1-associated mouse model of breast cancer.
Oncogene, 33 (47), 5477–5482. - Vichai, V., Kirtikara, K. (2006). Sulforhodamine B colorimetric assay for cytotoxicity screening.
Nature Protocols ,1 (3), 1112–1116. - Vinogradov, S., Wei, X. (2012). Cancer stem cells and drug resistance: The potential of nanomedicine.
Nanomedicine (Lond). ,7 (4), 597–615. - Wang, L., Li, P., Hu, W., Xia, Y., Hu, C., Liu, L., Jiang, X. (2017). CD44 + CD24 + subset of PANC-1 cells exhibits radiation resistance via decreased levels of reactive oxygen species.
Oncol. Lett., 14 (2), 1341–1346. - Weihua, Z., Lin, Q., Ramoth, A. J., Fan, D., Fidler, I. J. (2011). Formation of solid tumors by a single multinucleated cancer cell.
Cancer, 117 (17), 4092–4099. - Xiang, D., Shigdar, S., Bean, A. G., Bruce, M., Yang, W., Mathesh, M., Wang, T., Yin, W., Tran, P. H., Al Shamaileh, H., Barrero, R. A., Zhang, P. Z., Li, Y., Kong, L., Liu, K., Zhou, S. F., Hou, Y., He, A., Duan, W. (2017). Transforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery.
Theranostics .,7 (17), 4071–4086. - Zhang, S., Mercado-Uribe, I., Xing, Z., Sun, B., Kuang, J., Liu, J. (2014). Generation of cancer stem-like cells through the formation of polyploid giant cancer cells.
Oncogene ,33 (1), 116–128.
Language: English
Page range: 89 - 99
Submitted on: Nov 7, 2018
Accepted on: Feb 6, 2019
Published on: Apr 7, 2019
Published by: Latvian Academy of Sciences
In partnership with: Paradigm Publishing Services
Publication frequency: 6 times per year
Related subjects:
© 2019 Valdis Pirsko, Inese Čakstiņa, Dina Nitiša, Marija Samoviča, Zanda Daneberga, Edvīns Miklaševičs, published by Latvian Academy of Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.